Media OutReach
Diabetes Association Unveils T-CaReMe Taipei Declaration at the Asia Diabetes International Conference
In an effort to achieve a target of 80% of patients controlling the three highs and protecting kidney health within eight years, Taiwan leads the international trend of precise prevention with public-private collaboration in response to the new health goals of Healthy Taiwan.
TAIPEI, TAIWAN – Media OutReach Newswire – 28 March 2025 – As the global aging process accelerates, the prevention and care of chronic diseases have become a top priority for countries worldwide. The Taiwanese government has actively responded to international trends by promoting the “Healthy Taiwan” policy and launching the “Three Highs Prevention 888 Plan.” At the third “Healthy Taiwan Promotion Committee” meeting held last month, new goals were announced to reduce the standardized mortality rate of chronic diseases related to the three highs by one-third by 2030, aiming to strengthen chronic disease prevention and control measures through public-private collaboration. In alignment with the vision of “Healthy Taiwan” and the 888 Plan, and connecting with the international trend of “precision prevention” of chronic disease management, the Taiwan Diabetes Association formally presented the “T-CaReMe Precision Care Taipei Declaration” at the Asia Diabetes International Conference.
With a comprehensive national health insurance system in place, Taiwan ensures that every high-risk group can receive proactive prevention and personalized management early on, demonstrating international competitiveness in the accessibility and completeness of chronic disease care. To address the increasingly severe challenge of chronic diseases—particularly hypertension, hyperlipidemia, diabetes (the three highs), and chronic kidney disease—the Taiwan Diabetes Association unveiled the “T-CaReMe Precision Care Taipei Declaration” at the 17th Scientific Meeting of the Asian Association for the Study of Diabetes (AASD). This declaration was made in witness of various governmental agencies, academic institutions, and medical associations, including the Asian Association for the Study of Diabetes, the National Health Insurance Administration, the Health Promotion Administration, Academia Sinica, the National Health Research Institutes, the Taiwan Society of Nephrology, and the Taiwan Society of Cardiology. The declaration responds to the government’s vision of “Healthy Taiwan” and the goals of the 888 Plan, which focus on delaying disability and increasing life expectancy. It proposes a comprehensive health care model for chronic diseases centered around risk stratification, precision medicine, and digital management, further promoting the integration of holistic health care and medical services, while fostering interdisciplinary collaboration to drive a new paradigm of chronic disease prevention and treatment.
New Health Goals for Healthy Taiwan: Reduce Standardized Mortality Rate of Chronic Diseases Related to the Three Highs by One-Third
The Taiwan Diabetes Association Unveils T-CaReMe Declaration to Promote Precision Care Blueprint for Kidney Health in Relation to the Three Highs
With the trends of aging, prolonged illness, and the emergence of chronic diseases at younger ages, chronic disease prevention and management have become a global focus. Taiwan is following international trends by establishing the “Healthy Taiwan Promotion Committee,” which has set two major health goals for the next eight years: to increase the average life expectancy of the population from 79 to 82 years and to reduce the proportion of unhealthy life expectancy from 10% to 8%. To strengthen chronic disease management, the government recently announced a target at the Healthy Taiwan Promotion Committee meeting to “reduce the standardized mortality rate of chronic diseases related to the three highs by one-third by 2030,” along with comprehensive strategies promoting healthy lifestyles, obesity prevention, and holistic management of chronic diseases, through public-private collaboration to enhance health policies and reduce the risks of chronic diseases and disabilities.
The Taiwan Diabetes Association has released the “T-CaReMe Precision Care Taipei Declaration,” making “Kidney Protection in Relation to the Three Highs” a core focus. Through the T-CaReMe initiative, the vision of “risk stratification, precision medicine, digital management, and increased life expectancy” is implemented, along with five key action frameworks: promoting precise risk diagnostics, standardized clinical guidelines, personalized health management, data sharing, and interdisciplinary collaboration. The goal is to ensure that 80% of patients with the three highs and kidney disease achieve control of blood glucose, blood pressure, and blood lipids while ensuring that 80% of kidney disease patients receive care and medication guidance from care managers, thereby enhancing survival rates and improving health quality, creating a stronger defense for chronic disease care in the population.
Risk Stratification × Precision Medicine: T-CaReMe Initiative Launches a New Future for Chronic Disease Management
International Experts Gather to Establish Taiwan as a Demonstration Base for Chronic Disease Care
The T-CaReMe Taipei Declaration focuses on precise risk diagnostic classification and assessment, aiming to accurately identify high-risk populations and improve the effectiveness of chronic disease management. Through expert consensus and clinical risk stratification, as well as medical guidelines, the initiative integrates clinical data with international standards to ensure that patients receive personalized health management and appropriate treatment. Additionally, the declaration emphasizes collaboration across nations and disciplines, engaging in precision medicine and research achievements in the realm of chronic diseases in the Asia-Pacific region, influencing public health policies and improving chronic disease care outcomes, while developing a more precise and accessible holistic health care approach, solidifying Taiwan’s position as a regional demonstration base.
The meeting brought together experts and scholars from the National Health Insurance Administration, the Health Promotion Administration, Academia Sinica, and the National Health Research Institutes, along with representatives from the International Diabetes Federation (IDF-WPR) and the Asian Association for the Study of Diabetes (AASD), to witness the official launch of the “T-CaReMe Precision Care Taipei Declaration.” The Taiwan Diabetes Association stated that the declaration not only lays the groundwork for Taiwan’s development blueprint in precision chronic disease care and kidney health management related to the three highs but also aims to promote upgrades in chronic disease management models, enhance interdisciplinary collaboration, and build a more comprehensive health care system, driving improvements in global chronic disease care quality and prosperity starting from Taiwan.
Dr. Wu Mai-Su, President of the Taiwan Society of Nephrology, noted that although Taiwan has developed risk stratification and data-driven personalized treatment, standardized guidelines have yet to be incorporated, and clinical applications still have room for improvement, especially in the integrated management of kidney disease and diabetes. He expressed that through the T-CaReMe initiative, interdisciplinary collaboration can facilitate the integration of chronic kidney disease risk and comorbid management with diabetes and hypertension, contributing to higher patient survival rates and better kidney function maintenance. Dr. Li Yi-Heng, President of the Taiwan Society of Cardiology, emphasized that risk stratification and data-driven personalized management can effectively reduce the incidence of cardiovascular events, further strengthening the health defenses of the population. Dr. Hsu Hui-Heng, Deputy Director of the National Health Research Institutes, stated that the application of precision medicine will play a crucial role in future chronic disease management. The National Health Research Institutes is actively exploring several initiatives, such as using AI technology and big data to establish smart risk prediction systems, believing that under the visionary actions of the T-CaReMe initiative, there will be further optimization of precise predictions for cardiovascular, kidney, and metabolic disease risks, providing better scientific bases for the prevention of primary and secondary complications and organ damage associated with chronic diseases, thus realizing Taiwan’s health blueprint.
Aligning with International Standards! T-CaReMe Initiative Promotes a New Paradigm of Precision Chronic Disease Management
Taiwan will construct a comorbidity risk database within two years. The T-CaReMe initiative calls on all sectors to build a defense against chronic diseases.
In recent years, the Health Promotion Administration has actively promoted the “Scientific Disease Calculation Center” and risk prediction tools to enhance public health literacy and self-management awareness, delaying the onset of chronic diseases through proactive health education. Meanwhile, the National Health Insurance Administration has introduced AI risk stratification tools and a tiered care system, promoting the “Everyone’s Health Platform” and comprehensive, patient-centered care to improve care efficiency and resource utilization. Professor Chen Chih-Hong, Vice Convener of the Healthy Taiwan Promotion Committee, stated that the T-CaReMe initiative aligns closely with government policies integrating prevention and treatment, reflecting the core spirit advocated by the 888 Plan. In the future, it is hoped that all sectors will work together to deepen interdisciplinary collaboration and public-private integration, creating a sustainable and resilient model for chronic disease care.
The global healthcare community has identified precise risk assessment and personalized treatment as key trends in chronic disease management. The latest diabetes care guidelines particularly address the comorbidity risks associated with the three highs and kidney disease, suggesting earlier intervention in cardiovascular and kidney health management and enhancing data-driven diagnostic models. The importance of early screening and treatment is emphasized, and precise risk assessment and integration of patient data will be core development directions for future chronic disease management. These international trends indicate that global chronic disease management is moving towards precision medicine, digital monitoring, and interdisciplinary integration, which aligns closely with the goals of the T-CaReMe initiative.
The Taiwan Diabetes Association took action as early as 2023, collaborating with 12 medical institutions in Taiwan to join the iCaReMe global registry program. Through interdisciplinary integrated care, patient tracking, and the application of clinical data, it not only provides more precise risk assessments and patient profiles but also effectively monitors and optimizes treatment outcomes, which has been shown to improve patients’ health conditions. Chairman Huang Jian-Ning shared that the short-term goal of the T-CaReMe initiative is to construct a representative database within two years. By analyzing lifestyle factors, it aims to more accurately assess the comorbidity risks of different patients. Implementing a comprehensive model for precision chronic disease care requires not only efforts from the medical community but also active participation from government agencies, academic institutions, industry partners, and civic groups to jointly promote data integration and personalized health management, ensuring that risk stratification and standardized guidelines are continually refined, while enhancing chronic disease management effectiveness in Taiwan and the Asia-Pacific region.
Yutaka Seino, Chair of the Asian Association for the Study of Diabetes conference, stated that Taiwan has consistently been at the forefront of chronic disease prevention and treatment in Asia, and he hopes that through public-private collaboration and interdisciplinary cooperation, Taiwan can lead the global improvement of chronic disease care quality.
Hashtag: #DiabetesAssociation
The issuer is solely responsible for the content of this announcement.
Media OutReach
Global Wellness Forum 2026 Set for June 23 in Kuala Lumpur as Malaysia’s Nutraceutical Industry Embarks on Next-Gen Transformation
As a core component, James Pereira, general manager of MADSA, will share insights on Malaysian health industry regulations. Adrian Toh, CEO & Executive Director of R Pharmacy, will provide frontline retail channel observations regarding shifting consumer demands. Alex Liao, General Manager of Welbloom Bio-Tech, will represent Taiwan to share how format innovation effectively responds to brand differentiation, consumption experiences, and market compliance needs.
Faced with brands’ attention toward differentiated experiences, Welbloom Bio-Tech will showcase its proprietary, Halal-certified FRESH-Jelly® technology on-site, demonstrating the innovative application to make supplements more food-like. Through ingredient payload capacities, zero- or low-sugar designs, and customized flavor development, FRESH-Jelly® allows supplements to maintain functionality while becoming more enjoyable to consume regularly, providing Malaysian brands with a distinctive option beyond capsules and tablets.
With the rapid rise of Malaysia’s wellness consumer market, its mature distribution channels and exceptional potential for regional expansion are accelerating the country’s growth as a critical hub for the Southeast Asian health industry. Welbloom Bio-Tech states that this forum is a bridging platform connecting Taiwan’s manufacturing capabilities with Malaysian market insights, aiming to unlock commercially viable partnerships for both regions.
The event is organized by The PAGE, co-organized by Welbloom Bio-Tech and SEAbizs, and supported by NTBSA, MATRADE, R Pharmacy, and MADSA.
【Event Information】
Time: June 23, 2026, 09:30 – 14:00
Venue: The Zenith – Connexion Conference & Event Centre, Kuala Lumpur
Hashtag: #WelbloomBioTech
The issuer is solely responsible for the content of this announcement.
About Welbloom Bio-Tech
Welbloom Bio-Tech focuses on health supplement R&D, manufacturing, and dosage form innovation. Through forward-looking market foresight and robust R&D technologies, it provides one-stop services from formulation design and flavor development to manufacturing, assisting clients in Malaysia and Singapore to build highly competitive health supplements.
To learn more, please search “Welbloom” or click the link:
https://welbloom.com/malaysiaforum2026/
Media OutReach
Doing Good Index 2026: Asia’s US$753 Billion Philanthropic Potential Remains Unrealized
- Asia’s social sector is under strain: 78% of the 2,166 social delivery organizations (SDOs) surveyed report insufficient domestic funding.
- Asia is one of the fastest-growing regions for wealth creation, yet the policies and incentives needed to channel it toward social good are not keeping pace.
- Singapore has become the first economy to enter the “Doing Excellent” category, demonstrating what alignment across regulations, tax incentives, government partnerships and efforts to create a culture of giving can achieve.
- 84% of Asian SDOs surveyed apply the UN Sustainable Development Goals (SDGs) in their operations, pointing to their enduring value as a shared framework for coordination and collective action beyond 2030.
HONG KONG SAR – Media OutReach Newswire – 16 June 2026 – Asia’s social needs are intensifying, and official development assistance is declining. Yet, while the region’s wealth is growing dramatically, the policies, incentives and partnerships needed to channel private capital toward social good are not keeping pace. That is a key finding of the Doing Good Index 2026, the fifth edition of CAPS’s flagship policy report, which assesses the enabling environment for private social investment across 17 Asian economies.
The report finds that while the enabling environment for private social investment is in place across much of the region, its effectiveness remains uneven. Improvements in registration processes and accountability mechanisms have been accompanied by persistent barriers, including restrictions on foreign funding, regulatory complexity, and inconsistent government engagement. In many cases, policies exist on paper but are not fully implemented in practice, limiting their impact.
At the same time, although trust in SDOs remains high across the region, broader ecosystem conditions, such as media sentiment, talent pipelines, and institutional support, are showing signs of strain. 81% of SDOs struggle to secure unrestricted funds for their work, while 73% report difficulty recruiting staff, constraining the sector’s ability to turn trust into impact.
“Asia has the wealth, the will, and in many economies, the foundations of a strong enabling environment. What is needed now is concerted, aligned effort to bring them together. The potential is enormous,” said Ruth Shapiro, Co-Founder and CEO, Centre for Asian Philanthropy and Society.
Even as Asia’s wealth continues to grow, the region faces significant and intensifying challenges across climate, education and health. Official development assistance is declining, and there is increasing pressure on domestic resources at precisely the moment demand for social services is rising.
If Asian economies were to contribute just 2% of GDP to philanthropy, as the United States does, it could generate an estimated US$753 billion annually for social good. That represents 15 times the official development assistance flowing into the region, and almost half the financing needed to hit the UN’s SDGs in Asia. But realizing that potential depends on strengthening the policies, incentives and partnerships that enable private capital to flow toward social good. The Doing Good Index 2026 finds that across much of Asia, those conditions are not yet in place.
“The world has changed dramatically, and Asia can no longer rely on others to address its social challenges. The Doing Good Index 2026 shows the region has the potential to meet this moment, but only if governments and philanthropists act together to build the conditions that make it possible,” said Ronnie Chan, Chairman, Centre for Asian Philanthropy and Society.
Singapore Shows What Alignment Can Achieve
Singapore has, for the first time, entered the top “Doing Excellent” category in the Doing Good Index 2026, reflecting years of deliberate effort to build a strong culture of philanthropy and civic engagement. Clear regulations, generous tax incentives, openness to foreign funding, and close collaboration between government and the social sector have created a strong enabling environment.
Singapore’s achievement demonstrates that when regulations, fiscal policy, ecosystem conditions and procurement work in concert, the outcomes are stronger. While no two economies will follow the same path, Singapore’s experience highlights the conditions that matter, such as the active promotion and alignment of philanthropy and giving across the whole of society.
The SDGs: Falling Short but Still Relevant in Asia
In the run-up to 2030, global progress toward the SDGs has fallen short of ambition, and Asia is no exception. Yet the Doing Good Index 2026 finds that 84% of SDOs continue to apply the SDGs in their work. Further, the rise of Environmental, Social and Governance (ESG) reporting has not displaced them, because most SDOs see the two frameworks as complementary rather than competing.
As the deadline approaches, the Index points to their enduring value not as a target but as a shared framework for strategy, coordination and collective action in the years ahead.
Other Findings from the Report
- Talent shortages persist for Asia’s social sector: more than 70% of SDOs face difficulty recruiting and retaining staff across Asia.
- AI adoption is happening, but usage remains limited: only 13% of surveyed SDOs report using AI regularly.
- 39% of SDOs say claiming tax benefits is difficult, suggesting administrative barriers may be limiting the impact of existing incentives for giving.
Hashtag: #CAPS #DoingGood #PrivateCapital #PublicGood #Philanthropy #Impact
The issuer is solely responsible for the content of this announcement.
About the Doing Good Index
Released biennially and now in its fifth edition, the Doing Good Index is CAPS’s flagship policy research that assesses the enabling environment for doing good in Asia: the systems, policies and practices that facilitate or constrain philanthropic giving and the deployment of this capital.
CAPS’s research team surveyed 2,166 social delivery organizations (SDOs) and conducted 132 interviews with sector experts across 17 Asian economies to provide a comparative, evidence-based view of where environments are supportive, where gaps persist, and how systems can be strengthened to better mobilize private resources for public good.
The Index looks at indicators under four sub-indexes: regulations, tax and fiscal policy, ecosystem, and government procurement, which provide an understanding of the specific measures economies have taken to catalyze philanthropic giving and promote social sector development.
Since its inception, the Index has been an essential resource for policymakers, philanthropists, and nonprofit leaders seeking to understand and improve the conditions for giving across the region.
For more information, 
download the report and visit the Doing Good Index 2026 dedicated microsite.
About the Centre for Asian Philanthropy and Society (CAPS)
Established in 2013 and working across more than 17 economies in Asia, the Centre for Asian Philanthropy and Society (CAPS) is a nonprofit organization committed to improving the quantity and quality of philanthropic and private giving throughout Asia. Our mission is to maximize private capital for public good, conducting research, advisory, convening and capacity building to engage philanthropists, foundations, family offices, corporates, government bodies, social sector organizations and experts on best practices, models, policies and strategies to facilitate private giving and social investment in the region. For more information, visit www.caps.org and 
LinkedIn.
Rise vGPU + ModelHub Power China’s AI into the Heterogeneous Orchestration Era
HONG KONG SAR – Media OutReach Newswire – 15 June 2026 – Frost & Sullivan, a globally renowned growth consulting firm, has released its “2026 AI Infrastructure Orchestration Platform White Paper”. The report recognizes Phancy Group’s Rise vGPU as a Tier 1 Leading Platform, the highest maturity tier in heterogeneous GPU orchestration. Phancy’s ModelHub also achieved the highest Overall Score in the enterprise-grade model management platform evaluation. This marks a significant endorsement of Phancy’s technological capability in heterogeneous AI infrastructure.
According to the white paper, as large model applications scale rapidly, China’s AI industry is facing structural challenges stemming from multi-chip coexistence. These include hardware heterogeneity, fragmented software stacks, persistently low GPU utilization (generally below 30%), and rising model adaptation complexity — all of which have become major bottlenecks for enterprise-scale AI deployment.
The report highlights a fundamental shift in AI infrastructure competitiveness – moving away from “single-chip performance” toward “cluster-scale system coordination.” At this critical juncture, Phancy has positioned itself as a leader in advanced orchestration through its full-stack AI infrastructure platform, offering a proven solution to heterogeneous compute challenges and helping drive China’s AI industry from “compute accumulation” into a new era of “compute orchestration.”
Phancy Rise vGPU: Tier 1 Leading Platform
In its assessment of mainstream AI infrastructure platforms, Frost & Sullivan defined Tier 1 criteria across three core dimensions: heterogeneous support, fine-grained control, and production-grade execution. Phancy Rise vGPU meets all three standards and has been recognized as a Tier 1 Leading Platform.
Rise vGPU transforms AI infrastructure from fragmented, low-efficiency device-level management to a unified software-defined control plane. Its key technology breakthroughs include:
- Comprehensive Heterogeneous Management: Unified onboarding and management across more than 10 mainstream GPU/NPU vendors, including NVIDIA, Ascend, Cambricon, Hygon, and others.
- Ultra-Fine Resource Partitioning: Industry-leading sub-GPU level compute and MB-level memory granularity slicing.
- Significant Utilization Improvement: Through safe oversubscription and time/space multiplexing, GPU utilization is increased from industry averages below 30% to 70%-90%.
- Intelligent Precision Scheduling: Multi-dimensional scheduling algorithms based on priority, topology, load, and resource awareness to achieve optimal compute allocation.
- Production-Grade SLA Assurance: The Deterministic Execution Layer delivers committed and auditable SLA guarantees for critical inference workloads.
- Full Lifecycle Operability: Comprehensive monitoring, metering, and cost allocation capabilities that turn GPU resources into truly operable digital assets.
Model Hub: Highest Overall Score in Model Management Platform Evaluation
Beyond compute orchestration, the report underscores the strategic importance of enterprise-grade model management platforms. As a powerful complement to Rise vGPU, Phancy ModelHub enables enterprises to build a complete full-stack AI infrastructure — from compute to models and from resource scheduling to business delivery.
The white paper notes that Phancy ModelHub delivers leading performance in key areas such as Model & Chip Compatibility, Execution Stability & Performance, and Model-GPU Coordination & Scheduling, achieving the highest Overall Score. Through its unified model management and execution platform, ModelHub creates a seamless closed-loop process covering model onboarding, deployment optimization, inference services, and version governance — significantly lowering the barrier to model deployment and accelerating AI innovation.
Dr. Dai Wenyuan, Founder & CEO of Phancy, said: “The Frost & Sullivan white paper accurately captures the inflection point in AI infrastructure development. The recognition of Rise vGPU as a Tier 1 Leading Platform and ModelHub’s top Overall Score provide important authoritative validation of Phancy’s technology strategy and product strength. As a full-stack AI cloud service platform, Phancy believes the next wave of competitiveness in the AI industry will come from systematic improvements in compute orchestration efficiency. We will continue to focus on heterogeneous compute unified scheduling and model ecosystem operations, working closely with customers and industry partners to advance China’s AI industry from ‘compute accumulation’ to a true ‘compute orchestration’ era.”
Hashtag: #PhancyGroup
The issuer is solely responsible for the content of this announcement.
About Phancy Group
Phancy Group (6682.HK) is a leading full-stack AI cloud services platform, providing comprehensive solutions for the AI 2.0 era. Our offerings include Rise vGPU, ModelHub and SageAIOS, delivering efficient and scalable AI infrastructure with end-to-end capabilities. We provide a complete solution from heterogeneous compute resource management and optimization to the deployment of intelligent agent models. These solutions empower digital transformation across a wide range of industries, supporting our vision of building a large-scale and efficient “Token Factory.”
Guided by the mission of “AI for Everyone” and positioned as the “Navigator of AI,” Phancy Group is committed to becoming a global leader in Artificial General Intelligence.
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn